Search results for "time factor"

showing 10 items of 3219 documents

Sex-dependent changes in the pulmonary vasoconstriction potential of newborn rats following short-term oxygen exposure

2012

Chronic exposure to supplemental oxygen (O(2)) induces lung damage and mortality in a sex-dependent manner. The effect of short-term hyperoxia on the newborn pulmonary vasculature is unknown but is, however, of clinical significance in the neonatal resuscitation context. We hypothesize that short-term hyperoxia has a sex-dependent effect on the pulmonary vasculature.Following 1-h 100% O(2) exposure, the pulmonary arteries and lung tissues of newborn rats were evaluated.Superoxide dismutase 3 (SOD3) expression in female pups' lungs was increased as compared with that in the lungs of male pups. As compared with air-treated pups, the response of male pups to thromboxane was increased by O(2), …

MaleTime FactorsHypertension PulmonaryHyperoxiaPulmonary ArteryRats Sprague-DawleySex FactorsSuperoxidesPeroxynitrous AcidHypoxic pulmonary vasoconstrictionAnimalsVasoconstrictor AgentsMedicineFamilial Primary Pulmonary Hypertensionskin and connective tissue diseasesOXYGEN EXPOSURELungrho-Associated KinasesDose-Response Relationship DrugSuperoxide Dismutasebusiness.industryFree Radical ScavengersHydrogen PeroxideRatsUp-RegulationEnzyme ActivationDisease Models AnimalOxidative StressAnimals NewbornVasoconstrictionAnesthesiaPediatrics Perinatology and Child HealthFemalesense organsbusinessPediatric Research
researchProduct

The time course of recombinant production in Streptomyces coelicolor.

1971

SUMMARYThe process leading to gene recombination can be interrupted in the filamentous bacteriaStreptomyces coelicolorby growing mixed cultures on cellophane disks lying on complete medium. The mycelium is harvested, broken, diluted and the broken hyphae plated at different time intervals. By this means some markers can be excluded from heteroclones or from recombinant progeny in early samples. The recombinant pattern clearly changes with time, with an increase of markers contributed to the recombinant progeny. In crosses between male (NF) and female (UF) strains, the maleness is the first donor trait to appear in the cells of the recipient parent. The fertility factor does not produce a tr…

MaleTime FactorsHyphaBiologyGenetic recombinationlaw.inventionlawGeneticsMyceliumCrosses GeneticInfertility MaleRecombination GeneticSpores BacterialFertility factor (bacteria)fungiStreptomyces coelicolorChromosomeChromosome MappingGeneral MedicineChromosomes Bacterialbiology.organism_classificationMolecular biologyStreptomycesSporePhenotypeConjugation GeneticMutationRecombinant DNAGenetical research
researchProduct

Retrograde Recanalization of Chronic Total Occlusions in Europe: Procedural, In-Hospital, and Long-Term Outcomes From the Multicenter ERCTO Registry.

2015

BACKGROUND A retrograde approach improves the success rate of percutaneous coronary interventions (PCIs) for chronic total occlusions (CTOs). OBJECTIVES The authors describe the European experience with and outcomes of retrograde PCI revascularization for coronary CTOs. METHODS Follow-up data were collected from 1,395 patients with 1,582 CTO lesions enrolled between January 2008 and December 2012 for retrograde CTO PCI at 44 European centers. Major adverse cardiac and cerebrovascular events were defined as the composite of cardiac death, myocardial infarction, stroke, and further revascularization. RESULTS The mean patient age was 62.0 +/- 10.4 years; 88.5% were men. Procedural and clinical…

MaleTime FactorsIncidenceMiddle AgedCoronary AngiographySettore MED/11 - Malattie Dell'Apparato CardiovascolareHospitalsEuropeElectrocardiographyPercutaneous Coronary InterventionPostoperative ComplicationsTreatment OutcomeCoronary Occlusionchronic total occlusionsJ-CTO scoreChronic DiseaseHumansretrograde PCI revascularizationFemaleHospital MortalityProspective StudiesRegistrieschronic total occlusionFollow-Up StudiesJournal of the American College of Cardiology
researchProduct

Late postpancreatectomy hemorrhage after pancreaticoduodenectomy: is it possible to recognize risk factors ?

2012

Context Post-pancreatectomy hemorrhage is one of the most common complications after pancreaticoduodenectomy. Objective To evaluate the late post-pancreatectomy hemorrhage rate according to the International Study Group of Pancreatic Surgery criteria and to recognize factors related to its onset. Methods A prospective study of 113 patients who underwent pancreaticoduodenectomy was conducted. Late post-pancreatectomy hemorrhage was defined according to the criteria of the International Study Group of Pancreatic Surgery. Demographic, clinical, surgical and pathological data were considered and related to late post-pancreatectomy hemorrhage. Results Thirty-one (27.4%) patients had a post-pancr…

MaleTime FactorsIncidencePancreatectomy Hemorrhage Pancreatic FistulaHemorrhageComorbidityMiddle AgedCarcinoma NeuroendocrinePancreatic NeoplasmsAdenocarcinoma PapillaryPancreatic FistulaSettore MED/18 - Chirurgia GeneralePancreatectomyPostoperative ComplicationsRisk FactorsPancreatitis ChronicHumansFemaleProspective StudiespancreaticoduodenectomyAgedCarcinoma Pancreatic Ductal
researchProduct

Prolonged survival of Puumala hantavirus outside the host: evidence for indirect transmission via the environment

2006

The capability of rodent-borne viruses to survive outside the host is critical for the transmission dynamics within rodent populations and to humans. The transmission of Puumala virus (PUUV) in colonized bank voles (Clethrionomys glareolus) was investigated and additional longevity studies in cell culture with PUUV and Tula (TULV) hantaviruses were performed. Wild-type PUUV excreted by experimentally infected donor bank voles was shown to be transmitted indirectly between rodents through contaminated beddings, and maintained its infectivity to recipient voles at room temperature for 12–15 days. In cell culture supernatants, PUUV and TULV remained infectious for 5–11 days at room temperature…

MaleTime FactorsIndirect TransmissionPuumala virusViruslaw.inventionMice03 medical and health scienceslawVirologyChlorocebus aethiopsAnimalsVero Cells030304 developmental biologyHantavirusInfectivity0303 health sciencesbiologyArvicolinae030306 microbiologyHost (biology)Temperaturebiology.organism_classificationHousing AnimalVirology3. Good healthDisease Models AnimalTransmission (mechanics)Hemorrhagic Fever with Renal SyndromeEquipment ContaminationFemalePuumala virusBunyaviridaeJournal of General Virology
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Electrophysiology and neuronal integrity following systemic arterial hypotension in a rat model of unilateral carotid artery occlusion.

2007

Patients with carotid artery stenosis may be particularly susceptible to hypotension-associated cerebral ischemia and subsequent neurological sequelae. Measuring somatosensory evoked potentials (SEP), electroencephalogram (EEG), direct current (DC) potential, and histology, we compared the temporal evolution of cortical functional perturbations as well as neuronal integrity in a model of unilateral carotid artery occlusion and systemic hypobaric hypotension (HH) at the lower limit of cerebral blood flow autoregulation (50 mm Hg). Serial measurements of EEG power spectra as well as SEP-amplitudes and latencies of N10.3 were performed before, during, and up to 60 min after 30 min-HH (n=7) or …

MaleTime FactorsIschemiaWatershed strokeFunctional LateralityReaction TimeMedicineAnimalsCarotid StenosisRats WistarMolecular BiologyStrokeNeuronsAnalysis of VarianceCell Deathbusiness.industryGeneral NeuroscienceSpectrum AnalysisCortical Spreading DepressionElectroencephalographymedicine.diseaseRatsElectrophysiologyDisease Models Animalmedicine.anatomical_structureCerebral blood flowCerebral cortexSomatosensory evoked potentialCortical spreading depressionCarotid artery occlusionAnesthesiaNeurology (clinical)HypotensionbusinessDevelopmental BiologyBrain research
researchProduct

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (R…

2015

Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy…

MaleTime FactorsKaplan-Meier EstimateGastroenterologyLiver diseaseClinical endpoint610 Medicine & healthramucirumab sorafenib HCCAged 80 and overeducation.field_of_studyLiver NeoplasmsRemission InductionAntibodies MonoclonalMiddle AgedSorafenibTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaFemaleSurvival AnalysiHumanmedicine.drugAdultNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorPopulationAntibodies Monoclonal HumanizedPlaceboDisease-Free SurvivalDrug Administration ScheduleFollow-Up StudieRamucirumabDouble-Blind MethodInternal medicineConfidence IntervalsmedicineCarcinomaHumanseducationProportional Hazards ModelsAgedDose-Response Relationship Drugbusiness.industryPhenylurea CompoundsPatient Selectionmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryProportional Hazards ModelbusinessConfidence IntervalFollow-Up StudiesThe Lancet Oncology
researchProduct

Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type III

2006

International audience; Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels--for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C-->A and c.1032C-->G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor…

MaleTime FactorsKinins030204 cardiovascular system & hematologyMESH: Founder Effect[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityLinkage Disequilibrium0302 clinical medicineMissense mutationHereditary Angioedema Type IIIGenetics(clinical)MESH: Models GeneticGenetics (clinical)MESH: Heterozygote0303 health sciencesFactor XII[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyFounder EffectMarkov ChainsPedigree3. Good healthMESH: Linkage DisequilibriumFactor XIIHereditary angioedemaFemalemedicine.symptomMESH: Factor XIIHeterozygotemedicine.medical_specialtyMESH: MutationMESH: PedigreeMESH: Bayes TheoremCoagulation Factor XIIBiology03 medical and health sciencesMESH: Markov ChainsReportInternal medicinemedicineGeneticsHumansMESH: AngioedemaAngioedema030304 developmental biologyMESH: HumansModels GeneticAngioedemaHaplotypeMESH: Time FactorsBayes TheoremHeterozygote advantageMESH: Haplotypesmedicine.diseaseMESH: KininsMESH: MaleEndocrinologyHaplotypesMutationImmunologyMESH: Microsatellite RepeatsMESH: FemaleMicrosatellite RepeatsThe American Journal of Human Genetics
researchProduct

Endotoxin accelerates atherosclerosis independent of complement activation

2008

a Central Laboratory Animal Facility b Institute of Clinical Chemistry and Laboratory Medicine c Institute of Medical Microbiology and Hygiene, Johannes Gutenberg University, Mainz, Germany d Klinik fur Gefaschirurgie und Nierentransplantation, Heinrich Heine Universitatsklinik, Dusseldorf, Germany e Zentrum fur Medizin und Biowissenschaften, Forschungszentrum, Borstel, Germany f Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland g Department of Molecular Pathology, Graduate School of Medicine and Engineering, University of Yamanashi, Japan

MaleTime FactorsLibrary scienceHyperlipidemiasHematologyBiologyAtherosclerosisComplement C6Central laboratoryEndotoxinsC-Reactive ProteinCholesterolImmunologyAnimalsHumansFemaleRabbitsComplement ActivationTriglyceridesAnimal facilityThrombosis Research
researchProduct